The scientific backdrop is sobering. According to United Nations figures cited by the authors, roughly 800 million people worldwide were aged 65 or older in 2023, and the global elderly population is projected to surpass one billion during the 2030s. In China alone, 310 million people, about 22 percent of the population, are now aged 60 or over. Aging brings a cascade of tissue decline: sarcopenia, insomnia, coronary heart disease, and other conditions that erode quality of life and burden health systems. Disrupted circadian rhythms are among the earliest signals of aging in both humans and flies, appearing as phase advances and sleep fragmentation. Yet while the brain’s circadian circuitry has been studied extensively, the role of clock genes inside skeletal muscle during aging remained largely unexplored, a gap the new study set out to fill.

Tim occupies a distinctive position in biology because it is highly conserved from flies to humans and performs two jobs at once. In Drosophila, the molecular clock runs on a feedback loop: the CLK/CYC protein complex switches on transcription of the Per and Tim genes, whose protein products accumulate in the cytoplasm, shuttle into the nucleus, and shut their own genes down again until degradation resets the cycle. Light rapidly degrades TIM, allowing the clock to track the day-night cycle. In mammals, the Tim homolog has shifted evolutionarily toward cell-cycle control and genome maintenance; when DNA damage or replication stress strikes, TIM stabilizes replication forks and, together with the protein Tipin, helps activate the S-phase checkpoint, pausing the cell cycle long enough for repair. TIM also indirectly shapes metabolism, influencing glucose handling and energy balance through the clock’s downstream gene networks. What happens to these functions in aging muscle, however, was unknown.

To answer that question, the team exploited the genetic precision available in Drosophila. Using the Gal4/UAS system, they crossed flies carrying a Tim overexpression construct or a Tim RNA interference construct with flies carrying Mhc-Gal4, a driver that acts specifically in muscle. The resulting male offspring overexpressed, underexpressed, or normally expressed Tim exclusively in their muscles. Exercise was imposed with a rotating power tower apparatus: vials spun at 60 radians per second forced flies to repeatedly climb, with structured sessions totaling roughly an hour of activity per day, following a two-days-on, one-day-off rhythm for four weeks starting at two weeks of age. The researchers then measured 24-hour locomotor activity from video, climbing speed, heart rate and stroke volume captured by high-speed video of surgically exposed beating hearts, time to cardiac arrest under artificial hemolymph, and lifespan across groups of roughly 200 flies each.

The results from genetic suppression were striking. In one-week-old young flies, knocking down muscle Tim changed nothing measurable: activity, climbing speed, heart rate, stroke volume, and hypoxic cardiac failure time all remained normal. But by five weeks of age, the RNAi flies began falling apart. Their nighttime activity rose significantly, a signature of fragmented sleep, while climbing speed dropped, heart rate climbed, stroke volume shrank, hearts failed faster under hypoxia, and lifespan shortened. Aging itself pushed normal flies in the same direction, increasing nighttime activity and stressing the heart, but the Tim knockdown made everything worse. The overexpression experiment provided the mirror image: in aged flies, extra muscle Tim significantly reduced nighttime restlessness, boosted climbing speed, lowered heart rate, improved stroke volume, extended time to hypoxic heart failure, and lengthened lifespan, with no effect whatsoever in young flies. Tim, in other words, appears to govern how muscle ages, not how it develops or functions in youth.

Zooming into the muscle itself revealed the mechanism. Quantitative PCR and biochemical assays showed that Tim knockdown suppressed the expression of Clk, Sir2, and PGC-1alpha, reduced the mitochondrial respiratory chain complex I protein MRCC-I, decreased the expression of the contractile protein gene Mhc and its protein product, and lowered the activity of the antioxidant enzyme superoxide dismutase, all while reactive oxygen species accumulated. Transmission electron microscopy confirmed the damage visually: fewer mitochondria and frayed, disorganized myofibrils. Tim overexpression produced the opposite profile, upregulating the entire pathway, raising MRCC-I and SOD activity, cutting ROS, increasing mitochondrial abundance, and restoring myofibril integrity. The authors interpret this as a Timeless/Clock pathway working in parallel with a Timeless/Sir2/PGC-1alpha axis, with Sir2, the fly equivalent of the NAD+-dependent deacetylase SIRT1, promoting mitochondrial biogenesis and antioxidant defense through PGC-1alpha, a master regulator of energy metabolism.

The Sir2 connection carries real weight in aging biology. SIRT1 and related sirtuins protect heart and skeletal muscle by deacetylating and activating PGC-1alpha, which drives expression of mitochondrial assembly factors such as NRF1 and TFAM, and by activating the FOXO pathway to induce antioxidant enzymes like SOD2 and catalase. Aging depletes sirtuin levels in mammals, and SIRT1-deficient young mouse hearts show aging-like vulnerability to ischemia-reperfusion injury. What the fly study adds is the link upstream: for the first time, muscle Tim is shown to activate the Sir2/PGC-1alpha/MRCC-I pathway, positioning the circadian protein as a trigger for the mitochondrial machinery that keeps muscle and heart cells youthful.

Then comes the exercise twist. When the researchers subjected Tim knockdown flies, normal flies, and Tim overexpression flies to the four-week climbing regimen, exercise improved outcomes across all genetic backgrounds. Trained aged flies climbed faster, showed reduced overall and nighttime activity indicating better-consolidated sleep, had slower and stronger heartbeats with improved stroke volume, resisted hypoxic heart failure longer, and lived longer. Molecularly, exercise raised mRNA levels of Tim, Clk, Sir2, PGC-1alpha, and Mhc, elevated MRCC-I protein, increased mitochondrial number while reducing mitochondrial damage, boosted SOD activity, and lowered ROS. Critically, exercise upregulated Tim even in flies whose muscles were engineered for knockdown or overexpression, which positions exercise as an upstream regulator of the muscle Timeless gene rather than a bypass around it. The exercise program, in effect, retuned the same molecular circuit the genetic experiments had identified.

These findings dovetail with a broad literature showing that regular aerobic exercise ameliorates age-related sleep disturbances, preserves muscle mass, and reduces cardiovascular disease incidence, benefits that appear conserved from humans to flies. The molecular logic is also consistent: exercise raises NAD+ levels, enhancing Sirt1/Sir2 activity, which activates PGC-1alpha and FOXO to promote mitochondrial biogenesis and antioxidant capacity in muscle and heart. The new study welds these threads together by placing Tim above the sirtuin axis and showing that exercise pulls the same lever. Still, the authors are careful about limits. The Drosophila model diverges from mammalian biology; the mechanical rotation paradigm differs from voluntary human exercise; molecular measurements were confined largely to mRNA and protein levels without direct NAD+/NADH quantification or tissue-specific rescue experiments; only male flies were studied, leaving sex differences unexplored; and the precise upstream signal by which exercise, whether mechanical, metabolic, or redox-sensitive, elevates Tim expression remains unknown.

Even with those caveats, the implications are compelling. The work reframes skeletal muscle not merely as an engine of movement but as an endocrine and circadian organ whose internal clock helps time the aging of the whole organism, including the heart. If a conserved clock gene in muscle mediates exercise’s systemic benefits, future interventions might target the Timeless/Sir2/PGC-1alpha axis directly, whether through drugs that boost NAD+-dependent sirtuin activity, molecules that stabilize TIM, or exercise prescriptions optimized to stimulate the pathway. For now, the humble fruit fly has delivered a message that resonates far beyond the vial: when aging frays the body’s rhythms and weakens its heart, moving the muscles may reset the molecular clock that keeps both running.

Subject of Research: Muscle-specific Timeless gene regulation of exercise-induced protection against circadian, muscular, and cardiac aging in Drosophila

Article Title: Muscle‐Specific Upregulation of Timeless Mediates Exercise‐Induced Amelioration of Age‐Related Circadian Rhythm Disruption and Cardiac Dysfunction in Drosophila

Article References: Wen, D.-T., Lv, S., Sun, J.-Y., Chen, Y.-Q., Lin, Y., Du, Z.-R., Sun, G.-B., Yuan, T.-S., Shu, D., & Hou, W.-Q. (2026). Muscle‐Specific Upregulation of Timeless Mediates Exercise‐Induced Amelioration of Age‐Related Circadian Rhythm Disruption and Cardiac Dysfunction in Drosophila. Aging Cell, 25(9), Article e70708. https://doi.org/10.1111/acel.70708

Image Credits: AI Generated

DOI: 10.1111/acel.70708

Keywords: Timeless gene, circadian rhythm, exercise, aging, Drosophila, skeletal muscle, cardiac dysfunction, Sir2, PGC-1alpha, mitochondria, oxidative stress, sleep fragmentation

The biology underlying the problem begins with the receptor itself. HER2 is overexpressed in roughly 25 to 30 percent of breast cancers, and since its amplification was first linked to aggressive disease and poor survival in the 1980s, it has served as the archetype of a druggable oncogenic target. The monoclonal antibody trastuzumab, clinically available since the early 2000s, dramatically improved survival outcomes, an effect consolidated in landmark trials such as HERA, which reported asymptomatic declines in left ventricular ejection fraction in about 7 percent of patients, and BCIRG-006, where the figure climbed to 18.6 percent. A 2019 pooled analysis of the major adjuvant trastuzumab trials, encompassing HERA, NSABP B-31, and N9831, placed the prevalence of trastuzumab-related cardiotoxicity at 11.3 percent asymptomatic and 8.7 percent mildly symptomatic. Broader analyses put the incidence of cardiotoxicity at 14.3 percent with trastuzumab alone, rising to 17.9 percent when the dual antibody blockade of trastuzumab and pertuzumab is added.

The mechanistic explanation for this cardiac vulnerability is now reasonably well understood. Cardiomyocytes depend on HER2 signaling for survival and repair, and blocking the receptor triggers cardiomyocyte death through mitochondrial dysfunction and reactive oxygen species-dependent pathways, while also shifting the balance of anti-apoptotic and pro-apoptotic proteins within heart muscle cells. Trastuzumab additionally works through antibody-dependent cellular cytotoxicity, an immune mechanism that contributes to its anticancer potency but may compound cardiac injury. For patients whose left ventricular ejection fraction remains above 40 percent, the prospective SAFE-HEaRt study demonstrated that trastuzumab can be delivered with acceptable safety. Below that threshold, however, the evidence base thins dramatically, and trastuzumab is considered contraindicated. Guidance on preventing and monitoring cardiac dysfunction in cancer survivors exists, but for patients starting treatment with established cardiomyopathy and an ejection fraction below 40 percent, published guidance is scarce and the literature is sparse.

It was into this evidentiary vacuum that the Bengaluru patient arrived. A frail 65-year-old woman weighing just 38.5 kilograms, she had lived with ischemic cardiomyopathy since 2014 and was managing New York Heart Association class II heart failure with a regimen that included furosemide, aspirin, spironolactone, atorvastatin, carvedilol, digoxin, and nitroglycerin. In July 2023 she noticed a lump in her right breast. Biopsy revealed invasive breast carcinoma of grade 2, estrogen receptor positive in 15 percent of cells, progesterone receptor negative, HER2-positive with 3-plus staining in 95 percent of cells, and a Ki67 proliferation index of 25 percent. Imaging confirmed a heterogeneously enhancing lobulated mass in the lower inner quadrant of the right breast, along with necrotic deep pectoral lymph nodes, establishing early-stage disease that had not invaded skin or muscle. Baseline echocardiography, however, recorded a left ventricular ejection fraction of just 32 percent, placing trastuzumab and pertuzumab, the mainstays of HER2-positive breast cancer therapy, off the table.

The clinical team turned instead to lapatinib, an oral small-molecule tyrosine kinase inhibitor that dually targets HER2 and HER1. The pharmacological argument for this choice is layered. Pooled data from 3,689 patients across clinical trials, along with a meta-analysis of 26 studies, established that lapatinib carries a markedly lower cardiac risk, with reductions in ejection fraction, arrhythmia, and other cardiac adverse events occurring in roughly 3 percent of patients, and individual reports ranging between 1.6 and 4.5 percent. Unlike trastuzumab, lapatinib does not induce antibody-dependent cellular cytotoxicity, and it lacks the apoptosis-inducing property that contributes to cardiomyocyte death. Critically, its pharmacokinetic profile is far more forgiving: while trastuzumab circulates for a half-life of 16 days, pertuzumab for 18 days, and the antibody-drug conjugate T-DM1 for 4 days, lapatinib’s half-life is just 14.2 hours. That short duration means any adverse effect on the heart can be reversed rapidly, and the dose can be titrated or withheld entirely at short notice, an impossibility with long-acting antibodies that linger in the circulation for weeks.

The treatment plan was built around these pharmacological advantages. The patient received 12 weekly doses of nanoparticle albumin-bound paclitaxel together with lapatinib 250 milligrams once daily, with intravenous fluids restricted to avoid volume overload in her failing heart. A dedicated cardio-oncologist monitored her with weekly clinical assessments and monthly echocardiograms. After four weeks, the breast lump had shrunk from 4 by 3 centimeters to 2 by 2 centimeters, axillary nodes had diminished, and her ejection fraction held steady at 32 percent. Encouraged by her tolerance, the team escalated lapatinib to 500 milligrams daily and added weekly carboplatin. By eight weeks the tumor measured under 1 centimeter and cardiac function remained stable at 31 percent. A further escalation to 750 milligrams proved too much, producing increasing diarrhea that forced a return to the 500-milligram dose, a textbook illustration of how the oral agent’s dose flexibility allows real-time optimization in a way infusible antibodies cannot match.

After the full 12 weeks of neoadjuvant therapy, the patient requested a break to pursue local treatments. Positron emission tomography-computed tomography demonstrated a complete metabolic response, confirming that the tumor had been eradicated morphologically and metabolically. Surgery, however, presented an unacceptable risk. Given her ejection fraction of 32 percent with dilated cardiomyopathy, the Seattle Heart Failure Model predicted a five-year mortality of 35 percent, and the patient declined to accept the high probability of peri-operative cardiac complications even after cardiology clearance. The team pivoted to definitive external beam radiation to the right breast, supraclavicular fossa, and axilla, delivering 40 Gy in 15 fractions with a 12.5 Gy boost in 5 fractions to the tumor bed, followed by hormonal therapy with an aromatase inhibitor for five years and continued lapatinib for up to two years. At two years of follow-up, she remains free of disease on clinical examination and imaging, with her cardiac function never having deteriorated during treatment.

The case carries implications beyond a single patient. The authors note that to their knowledge this is the first published description of neoadjuvant lapatinib-based therapy for HER2-positive breast cancer in a patient with pre-existing cardiomyopathy and an ejection fraction below 40 percent, and they frame it as highlighting a genuine gap in the literature. Newer and more potent HER2-targeted kinase inhibitors may extend this strategy: neratinib and tucatinib have both shown cardiac dysfunction rates below 3 percent in pivotal trials, suggesting a growing armamentarium of heart-sparing oral agents for this vulnerable population. The authors also acknowledge the trade-off candidly, noting that lapatinib may be less effective than monoclonal antibodies at engaging immune pathways through antibody-dependent cellular cytotoxicity. In this patient, however, that pharmacological compromise proved more than sufficient, delivering a complete metabolic response without a single beat of additional cardiac damage. For the growing cohort of cancer patients with compromised hearts, the case offers a practical roadmap: choose agents with short half-lives, titrate carefully under dedicated cardio-oncology surveillance, and let pharmacokinetics do the protective work that antibodies cannot.

As targeted cancer therapy continues to expand, the intersection of oncology and cardiology will only grow more crowded. Cardio-oncology, the discipline embodied by the monthly echocardiographic monitoring in this case, is rapidly becoming an essential partner in curative cancer care. The Bengaluru report demonstrates that a contraindication on a drug label need not translate into a forgone chance at cure. By understanding the molecular reasons why HER2 blockade injures the heart, and by selecting inhibitors whose kinetics allow rapid withdrawal, clinicians can walk the tightrope between tumor and myocardium, and occasionally, as in this case, reach the other side with both the cancer and the heart intact.

Subject of Research: Use of the HER2-targeted tyrosine kinase inhibitor lapatinib to treat HER2-positive breast cancer in a patient with pre-existing cardiac dysfunction

Article Title: Targeting HER-2 pathway in presence of cardiac dysfunction: the walk on a tight rope

Article References: Simha, V., Raj, B., Munirathna, V., & Anantharamu, S. (2026). Targeting HER-2 pathway in presence of cardiac dysfunction: the walk on a tight rope. Clinical Cancer Bulletin, 5(1), Article 12. https://doi.org/10.1007/s44272-026-00064-4

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00064-4

Keywords: HER2-positive breast cancer, lapatinib, cardiotoxicity, trastuzumab, cardiac dysfunction, tyrosine kinase inhibitor, neoadjuvant chemotherapy, cardio-oncology, ejection fraction, pertuzumab, drug safety, clinical case report